Exhibit 99.1 Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update - Commenced market launch and first commercial sales of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma - - Total revenues of $517,000 for quarter from sales and collaborative research agreement – - Completed public offering raising$46.7 million in net proceeds - - Implemented cost reduction to extend cash runway - ---Conference call today at 8:30am ET - DURHAM ...